“Renovacor is in a similar situation to the one MyoKardia was in five years ago,” says Dr. Semigran. “We have knowledge of the mechanism of action of dilated cardiomyopathy, where there’s an inadequate amount of a required protein for the heart muscle to function correctly. And fortunately, I think the field of selective gene therapy for the heart has evolved to the point that we’ve got a pretty good chance of targeting the underlying abnormality of the segment of the cardiomyopathy population with a BAG3-associated condition.”